Concord Biotech Q2 profit slides 34%; board clears new ventures

CNBC TV18

Concord Biotech Ltd on Thursday, November 13, reported a 33.6% year-on-year decline in its net profit at ₹63.6 crore for Q2FY26, compared to ₹95.7 crore in the same period last year.

The company's revenue

also declined 20.4% to ₹247.1 crore from ₹310.2 crore.

Earnings before interest, tax, depreciation, and amortisation (EBITDA) fell 35.3% to ₹88.4 crore. The operating margin slipped to 35.8% from 44% a year ago.

The company’s board has approved a proposal to acquire 100% equity in Celliimune Biotech Pvt Ltd, marking a strategic expansion move in the biotech segment, stated the company's exchange filing.

Additionally, the board cleared an investment of up to ₹10 crore in a captive hybrid solar power project for its Limbasi plant, reinforcing the company’s commitment to sustainable operations.

Shares of Concord Biotech Ltd ended marginally higher on Thursday, November 13, by 0.04% at ₹1,463.80 on the NSE.

Also Read: TVS Supply Chain Q2 Results | Net profit spikes 54% on cost efficiency, strong execution

Do you find this article useful?

Concord Biotech Q2 profit slides 34%; board clears new ventures

More stories you might like

Thermax shares fall 4% after weak Q2; profit, margins miss estimates

Afcons Infra Q2 Results: Shapoorji Pallonji co sees 22.5% drop in profit, revenue up 1%

Pfizer Q2 net profit rises 19% YoY; strong growth in sales and margins

Kirloskar Oil Engines Q2 results: Net profit, revenue show robust gains on good B2B show

Landmark Cars turns profitable in Q2 with ₹1.2-cr net profit; revenue jumps 34%

Gujarat Narmada Valley Fertilizers Q2 profit surges 70%, margins nearly double

MPS Q2 Results: Stock jumps after revenue grows nearly 10%, margin expands

Syrma SGS Technologies Q2: Net profit nearly doubles, revenue up 37.6%

Surya Roshni Q2: Net profit up 117%, revenue up 21%

Finolex Cables Q2 Results: Net profit and revenue grow from last year

AI Generated